Compare Ferrari NV (RACE) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Zimmer Biomet Holdings Inc — how do they compare? Ferrari NV trades at $389.91 (market cap $67.35B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Ferrari NV is far larger — about 4× Zimmer Biomet Holdings Inc's market cap, and Ferrari NV pays the higher dividend (1.09%). Which is the better fit depends on your goals — on Pluang, investors hold Ferrari NV for 126 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| RACE | ZBH | |
|---|---|---|
Market Cap | $67.35B | $16.95B |
Volume | 390,618 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $436.54 | $103.98 |
52-Week Low | $314.63 | $79.58 |
Typical Hold Time | 126 Days | 89 Days |
Enterprise Value | $69.22B | $24.02B |
Dividend Yield | 1.09% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $388.28, up 0.49% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $7.15B in 2025, with a net income margin of 22.25% and robust ROE of 45.45%. The company is executing a share buyback program and recently announced a partnership with Rakuten effective January 2027.
The outlook is positive given strong profitability, consistent earnings beats, and analyst consensus favoring a buy rating with a $462.75 price target. Risks include high valuation multiples (P/E 37.19) and exposure to economic cycles affecting luxury demand. Institutional buying and buyback support provide downside cushion, but investors should monitor execution on future growth initiatives.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
